Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
about
A kinase-independent role for EGF receptor in autophagy initiationMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaEpidermal growth factor receptor inhibitors: coming of ageSquamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelinesFrom Normal Skin to Squamous Cell Carcinoma: A Quest for Novel BiomarkersEvolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategiesMolecular changes in the multistage pathogenesis of head and neck cancerSpecific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinomaRegulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyPhase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.Selective Killing Effects of Cold Atmospheric Pressure Plasma with NO Induced Dysfunction of Epidermal Growth Factor Receptor in Oral Squamous Cell CarcinomaPharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neckA phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsCetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.Targeting the epidermal growth factor receptor for head and neck cancer chemopreventionRandomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Gemcitabine for the treatment of advanced nonsmall cell lung cancerEffect of bisphosphonates on pain and quality of life in patients with bone metastases.A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckEpidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckCurcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.Tongue carcinoma infrequently harbor common actionable genetic alterationsPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisCombination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancerA colliding maxillary sinus cancer of adenosquamous carcinoma and small cell neuroendocrine carcinoma--a case report with EGFR copy number analysis.Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7Collateral Lethality: A new therapeutic strategy in oncologyEGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
P2860
Q24314943-07F444FC-5463-4589-856D-9234D9180DEAQ26750719-9A01290D-5BA3-4DF3-BD18-256BC5B5AAEFQ26765429-D015AFE2-309E-4D16-AF9F-93465EE8CCB2Q26852215-00A8DA25-F48F-484D-A12F-A9758AF68FA3Q26991953-A2ABB90C-4453-442B-A794-8CA3B3BF38FDQ27030769-81FAED83-E432-4B50-BE97-04164C9CD79EQ27686904-5179ED06-581D-48EF-BF81-888CC096AB94Q28078702-A820DE6F-138F-4BB1-9A20-68A1EDAC2D20Q28471733-DAF8DC83-0DE5-4E6D-9E9E-5FCAF2C0DD5CQ28728638-5545CE30-4FB1-44B6-A3DD-D60AB3FF2A72Q28732052-EE2F2185-79FA-4341-947F-CFC8D8791D2FQ28749302-31D1DED9-69AD-4325-8DFF-D8C815674B44Q30424348-CA168281-65A4-4DA8-B730-387E9B493C56Q30430971-361E02E9-3158-41E4-955E-194F42BEAC98Q30557865-D5C17F7C-C9F0-42CF-B1EA-C1089DFC477AQ33406802-C2A0405D-AFAE-4E0C-9060-EC462F9B02D6Q33412801-54DFAB23-C244-4FD7-A442-0CA0936DCEADQ33434648-5086CAD5-96DC-432F-906C-03C48DE078A9Q33467304-32F2227B-7454-4BB2-AD8B-DBCB182967E9Q33551899-DEB7ED5B-6B6A-48B1-9DF2-BD8CDB5D4465Q33621754-A9609FE9-D083-44EB-8834-5758595E3F86Q33732128-2F0C29CF-5B40-4478-AD42-C4CB579035DAQ33767100-7E453909-A9AE-49BA-84C5-C0AF851D3ABDQ33875694-F61F7D27-57D8-4AF8-9A84-1322240EA389Q33895537-D1ED3A4C-2972-4FC9-8CD5-F44D8D0BB92DQ33915997-AC7E9042-5151-4345-B411-A7315B53A0E8Q34015944-AE83950C-304C-4A85-A70E-D2CA80BF1B2CQ34083131-53AD7AB1-3FE6-4BBA-98B1-A487080B8035Q34159125-996D928D-0F3E-442D-A8CB-56DC9C9B4BAEQ34163076-DB23D0E0-EF20-48A6-B054-CE317583E913Q34256064-ABE9C3DE-256A-48ED-82A7-B7D2CF0DA1EBQ34272887-BEB84155-008A-4B06-B751-F5AAD8BBBF49Q34318204-532D2D45-CAE6-456E-AB4A-6465D9C33C94Q34321496-E1D88D51-1DEA-4B35-A68E-7F06E1D5E439Q34463471-DCAF55E5-A4B8-41E5-8111-6B52109356D4Q34513800-5B0419B1-0A42-4D31-B2C5-CEEE52224E69Q34618994-101EF5AC-7777-4EEE-B190-48AABE2E6E93Q34639763-86A65CF5-AB1A-483C-AC20-B9401678A43EQ35050662-18771BC3-2907-4EBD-9234-3E8A3EDF34D5Q35050740-B2BB4A7F-AF0D-4DFA-BEAA-045E7A8FCBF4
P2860
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Multicenter phase II study of ...... l cancer of the head and neck.
@ast
Multicenter phase II study of ...... l cancer of the head and neck.
@en
Multicenter phase II study of ...... l cancer of the head and neck.
@nl
type
label
Multicenter phase II study of ...... l cancer of the head and neck.
@ast
Multicenter phase II study of ...... l cancer of the head and neck.
@en
Multicenter phase II study of ...... l cancer of the head and neck.
@nl
prefLabel
Multicenter phase II study of ...... l cancer of the head and neck.
@ast
Multicenter phase II study of ...... l cancer of the head and neck.
@en
Multicenter phase II study of ...... l cancer of the head and neck.
@nl
P2093
P356
P1476
Multicenter phase II study of ...... l cancer of the head and neck.
@en
P2093
Denis Soulieres
Lillian L Siu
Neil N Senzer
Sanjiv S Agarwala
P356
10.1200/JCO.2004.06.075
P407
P577
2004-01-01T00:00:00Z